Nasdaq

Sana Biotechnology to Present First-in-Human Clinical Data on Hypoimmune Islet Cell Therapy for Type 1 Diabetes at ADA Scientific Sessions

Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...
Seeking Alpha

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...
Nasdaq

Sana Biotechnology, Inc. Reports Positive 12-Week Clinical Results for Type 1 Diabetes Therapy and Financial Overview for Q4 2024

Sana Biotechnology, Inc. announced encouraging preliminary results from a 12-week clinical study involving hypoimmune-modified pancreatic islet cells for type 1 diabetes, showing persistent C-peptide ...